Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.
about
Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trialSafety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analy
P2860
Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Insulin degludec/insulin aspar ...... of type 1 and type 2 diabetes.
@en
type
label
Insulin degludec/insulin aspar ...... of type 1 and type 2 diabetes.
@en
prefLabel
Insulin degludec/insulin aspar ...... of type 1 and type 2 diabetes.
@en
P2860
P921
P356
P1476
Insulin degludec/insulin aspar ...... of type 1 and type 2 diabetes
@en
P2093
Angela Dardano
Roberto Miccoli
P2860
P304
P356
10.2147/VHRM.S40097
P407
P5008
P577
2014-08-05T00:00:00Z